Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Geoffrey Yuen"'
Autor:
Tianhong Li, Patricia LoRusso, Michael L. Maitland, Sai-Hong Ignatius Ou, Erkut Bahceci, Howard A. Ball, Jung Wook Park, Geoffrey Yuen, Anthony Tolcher
Publikováno v:
Journal of Hematology & Oncology, Vol 9, Iss 1, Pp 1-9 (2016)
Abstract Background ASP3026 is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that has potent in vitro activity against crizotinib-resistant ALK-positive tumors. This open-label, multicenter, first-in-human phase I study ( NCT01284192
Externí odkaz:
https://doaj.org/article/6df78f3e3340454c8deb3c23b520004a
Autor:
Jorge Chaves, Stanley C. Gill, Elizabeth Conklin, Srinivasu Poondru, Margaret Singh, Barbara Parker, Masanori Nagata, Geoffrey Yuen
Publikováno v:
Cancer chemotherapy and pharmacology. 77(4)
This study characterized the pharmacokinetics, mass balance, routes and extent of elimination, metabolites, and safety of a single oral dose of 14C-linsitinib, an IGF-1R/IR inhibitor, in patients with advanced solid tumors. The tolerability of linsit
Autor:
Charles Liu, Takeshi Kadokura, Jessica K. Altman, Alexander E. Perl, Catherine C. Smith, Geoffrey Yuen, Angela Joubert James, Peter L. Bonate, Erkut Bahceci, Itsuro Nagase, Ogert Fisniku, Mark J. Levis, Mark R. Litzow, Stan Gill
Publikováno v:
Journal of Clinical Oncology. 34:7026-7026
7026Background: Gilteritinib, also known as ASP2215, is a selective FLT3 inhibitor in development for the treatment of acute myeloid leukemia (AML). In ongoing trials, gilteritinib has demonstrated...
Autor:
Mark J. Levis, Ogert Fisniku, Itsuro Nagase, Alexander E. Perl, Briana Sargent, Geoffrey Yuen, Jessica K. Altman, Takeshi Kadokura, Catherine C. Smith, Charles Liu, Mark R. Litzow, Stanley C. Gill, Erkut Bahceci, Noreen Welter
Publikováno v:
Blood. 126:4836-4836
Introduction: ASP2215, a new tyrosine kinase inhibitor with activity against FMS-like receptor tyrosine kinase-3 (FLT3) and AXL receptor tyrosine kinase, is currently in development for the treatment of acute myeloid leukemia (AML). Methods: In an on
Autor:
Kyriakos P. Papadopoulos, Erkut Bahceci, Patricia LoRusso, Muaiad Kittaneh, Amita Patnaik, Anthony W. Tolcher, H. A. Ball, Geoffrey Yuen
Publikováno v:
Journal of Clinical Oncology. 31:2602-2602
2602 Background: ASP3026 (3026) is a selective, potent, ATP-competitive, small molecule oral inhibitor of ALK receptor tyrosine kinase that has not previously been tested in humans. A Phase 1 dose-escalation trial, using a 3+3 design, evaluating 3026